|
|
Volumn 5, Issue 9, 2006, Pages 715-716
|
|
Hepatitis C virus therapies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALBUMIN ALPHA INTERFERON;
ANA 975;
ANTIVIRUS AGENT;
BETA1A INTERFERON;
CILUPREVIR;
CPG 10101;
HCV 796;
IMMUNOMODULATING AGENT;
INTERFERON;
ITMN 191;
LOCTERON;
METHYLENE BLUE;
MULTIFERON;
NUCLEOSIDE ANALOG;
OMEGA INTERFERON;
PEGINTERFERON;
PEGINTERFERON ALPHA2A;
PEGINTERFERON ALPHA2B;
PRODRUG;
PROTEINASE INHIBITOR;
R 1626;
RECOMBINANT ALPHA2B INTERFERON;
RIBAMIDINE;
RIBAVIRIN;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SCH 503034;
SUVUS;
TARIBAVIRIN;
THYMOSIN ALPHA1;
UNCLASSIFIED DRUG;
VALOPICITABINE;
VX 950;
ANEMIA;
CARDIOTOXICITY;
CLINICAL TRIAL;
DRUG POTENTIATION;
GASTROINTESTINAL SYMPTOM;
GENOTYPE;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
NONHUMAN;
NOTE;
PATIENT CARE;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
ANTIVIRAL AGENTS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DRUG THERAPY, COMBINATION;
HEPACIVIRUS;
HEPATITIS C;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
PREVALENCE;
PROTEASE INHIBITORS;
TREATMENT OUTCOME;
WORLD HEALTH;
|
|
EID: 33748288279
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2134 Document Type: Note |
|
Times cited : (18)
|
|
References (2)
|
